論文

査読有り 国際誌
2020年4月26日

Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

British journal of haematology
  • Takahiro Aoki
  • ,
  • Hiroyuki Takahashi
  • ,
  • Shiro Tanaka
  • ,
  • Norio Shiba
  • ,
  • Daiichiro Hasegawa
  • ,
  • Shotaro Iwamoto
  • ,
  • Kiminori Terui
  • ,
  • Hiroshi Moritake
  • ,
  • Hideki Nakayama
  • ,
  • Akira Shimada
  • ,
  • Katsuyoshi Koh
  • ,
  • Hiroaki Goto
  • ,
  • Yoshiyuki Kosaka
  • ,
  • Akiko M Saito
  • ,
  • Keizo Horibe
  • ,
  • Akitoshi Kinoshita
  • ,
  • Akio Tawa
  • ,
  • Takashi Taga
  • ,
  • Souichi Adachi
  • ,
  • Daisuke Tomizawa

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/bjh.16656

The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.

リンク情報
DOI
https://doi.org/10.1111/bjh.16656
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32337716

エクスポート
BibTeX RIS